Hamps Bio Ltd., a niche player in pharmaceutical formulations and freeze-dried food products, has announced a board recommendation for issuing bonus shares, marking a shareholder-centric move aimed at enhancing liquidity and reinforcing investor confidence. The announcement was made on July 29, 2025, and is expected to be ratified in the upcoming shareholder meeting.
This proposed bonus issue reflects the company’s improving financial health and its intent to widen retail participation in its equity base.
Key Highlights of the Bonus Share Proposal
The Board of Directors has recommended a bonus issue in the ratio of 1:2, meaning shareholders will receive 1 bonus share for every 2 shares held
The bonus shares will be issued from the company’s free reserves, subject to shareholder approval
Record date and ex-bonus date will be announced post-approval, likely in Q2 FY26
The bonus issue will not involve any cash outflow and will proportionally increase the number of outstanding shares
This move is expected to reduce the per-share price, making Hamps Bio’s stock more accessible to retail investors and improving overall trading volumes.
Strategic Rationale Behind the Bonus Issue
Shareholder Reward and Market Visibility
The bonus issue is a non-dilutive way to reward long-term shareholders
It enhances visibility and attractiveness of the stock in the SME segment
Liquidity Enhancement
A higher number of outstanding shares typically leads to improved liquidity and price discovery
Facilitates easier entry for new investors and better exit options for existing holders
Confidence in Financial Reserves
The company’s ability to issue bonus shares reflects strong retained earnings and balance sheet stability
Signals management’s confidence in future cash flows and profitability
Hamps Bio had previously issued bonus shares in June 2024 in a 3:5 ratio, and this latest proposal continues its trend of shareholder-friendly capital actions.
Financial Context and Performance Trajectory
Hamps Bio has shown steady growth in its top and bottom lines over the past fiscal periods:
FY24 revenue stood at Rs 6.50 crore with net profit of Rs 0.50 crore
For the seven months ended October 2024, the company posted Rs 4.36 crore in revenue and Rs 0.34 crore in net profit
The company generates over 87% of its pharma segment revenue from Gujarat and 63% of its freeze-dried food segment revenue from domestic markets
The bonus issue is expected to further strengthen investor sentiment, especially as the company expands its e-commerce footprint and product portfolio.
Market Reaction and Investor Implications
The announcement has sparked renewed interest in Hamps Bio’s stock, which has seen increased trading activity on BSE SME
Analysts expect the bonus issue to improve retail participation and broaden the shareholder base
Investors should monitor the upcoming shareholder meeting for final approval and key dates
Post-bonus, the company’s paid-up equity capital will increase, but ownership percentages will remain unchanged. The move is purely cosmetic in terms of valuation but impactful in terms of market dynamics.
Conclusion
Hamps Bio Ltd.’s proposed bonus issue in a 1:2 ratio reflects a strategic blend of financial prudence and shareholder engagement. As the company continues to scale its pharma and freeze-dried food businesses, this capital action reinforces its commitment to inclusive growth and market transparency.
Source: Rediff MoneyWiz – July 29, 2025 The Economic Times – July 29, 2025 Trendlyne – July 29, 2025 MoneyWorks4Me – July 29, 2025 Chittorgarh.com – July 29, 2025 BSE India – July 29, 2025
